RetinAI develops software solutions to generate and organize insights and knowledge to improve patient outcomes. The company provides end-to-end digital solutions to accelerate R&D of first-in-human drug candidates, supercharge clinical studies, and elevate the quality of care for patients.
Its platform, Discovery, enables healthcare professionals and pharmaceutical companies to manage medical data, perform AI-powered analysis, and enhance clinical and research workflows. The platform is CE-marked and FDA-cleared, supporting ophthalmology with tools for data harmonization, visualization, and global collaboration.
RetinAI focuses on ophthalmology, offering AI models for retinal imaging analysis, real-world evidence generation, and precision medicine applications.
